SUMMARY The clinical and serological features have been analysed retrospectively in 42 patients with an onset of systemic lupus erythematosus (SLE) up to 16 years of age. Thirty-seven (88 -1 %) were female and 5 (11 9 %) male. The mean age of onset was 12 3 years (range 7-16); 11 patients were 10 years or under. The mean duration of disease from diagnosis was 7 1 years (range 6 months-25 years). There were 6 deaths, 3 from infection, 2 from renal failure, and 1 from heart failure. Survival was calculated both from the date of onset and from the date of diagnosis. With the latter the estimated overall survival at 5 years was 82 -6 and at 10 years 76 -1 %. The survival for patients with lupus nephritis was 59 5 % at 5 years and 47 6 % at 10 years. These data suggests that SLE in childhood is not necessarily associated with a poor prognosis, though renal involvement is still serious. There appeared to be no major differences between prepubertal, adolescent, and adult SLE with respect to clinical and serological findings.
Reports on childhood SLE in the past 25 years have provided conflicting views on its course and prognosis.1-10 During the past decade a more widespread awareness of the disease, as well as the development of newer diagnostic techniques, has led to a recognition that the course and overall prognosis of SLE is less grave than previously thought.8 3 The aims of this study were to analyse retrospectively the clinical and laboratory findings and prognosis in childhood systemic lupus erythematosus.
Patients and methods
Forty-two patients whose disease developed at the age of 16 
Results
Of the 42 children 37 were female (88-1 %) and 5 male. Forty children were Caucasian, 1 Kenyan Indian, and 1 Negro. The mean age of onset was 12 3 years and the mean age at diagnosis was 13 * 5 years. The mean time between estimated onset and diagnosis was 1-2 years, with the longest time between onset and diagnosis 11 years. The number of patients with an onset of disease at 10 years of age or less was 11 (26 1 %), 31 being aged 11 or more; all the males belonged to the latter group. The peak age of onset was at 14 to 15 years of age for girls (Fig. 1) .
The initial manifestations are shown in Table 1 . Hydroxychloroquine in a dose of 200 mg/m2'/day was used in 9 patients. Fifteen patients received immunosuppr-essive drugs in the fornm of azathioprine (2 mg/kg/day) in 10 patients either for renal disease (8) or vascuLlitis ( I) or central ner-vous system involvement (1). Cyclophosphamide (2-2-5 mg/kg/ day) was administered to 5 patients, and all had renal involvement with severe systemic disease. Plasmapher-esis was used in only 3 patients, all of whom had nephlitis andi systemic disease.
Prognosis. The 42 patients were followed tIp for periods of one-half to 25 years following diagnosis (mean dulrationi 7 1 years). There were 6 deaths (14 2%o), 4 of females and 2 of males, all occurring within the first 6 years of the disease. Infection (septicaemia, pneumonia, gangrene of the leg) in association with active SLE and corticosteroid treatment was the cause of death in 3 patients. Renal failure was the terminal event in 2 patients and heart failure and hypertension associated with renal failure in I (Table 4) . At the present time, of the Years from the diagnosis surviving 36 patients 4 are in remission needing no medication, 15 are either asymptomatic or have mild symptoms and are being maintained on small doses of corticosteroids (less than 10 mg of prednisolone a day). Twelve patients with active disease are receiving higher doses of corticosteroids (more than 10 mg of prednisolone a day in 5 cases and/or immunosuppressive drugs in 7 cases). Five patients have been lost to follow-up. Survival was calculated from the time of diagnosis as the starting point.15
The estimated survival for the whole group of patients at 5 years was 82-6 % and at 10 years 76 * 7 % (Fig. 4) . From the first symptom as starting point the estimated 5-years survival was 86 % and 10-years survival was 76 8 %. Two deaths occurred within the first year of diagnosis, 2 in the second year, and 1 each in the fourth and fifth years. Estimated survival rates for patients with and without renal involvement differed strikingly. From the time of the diagnosis as the starting point no deaths occurred in the nonnephritic group. In the group with nephritis the 5-years survival was of 59 5 % and the 10-years survival 47-6% (0-025>/2>0.010) (Fig. 5) From the time of diagnosis as the starting point the survival curve for the whole group at 5 years was 82=6% and at 10 years 76-7%. The development of renal disease had a marked influence on the survival, though death was not necessarily due to renal failure. In the group with renal involvement the 5-years survival was 58 * 5 % and the 10-years survival 47 6 %.
There were no deaths in the group without renal disease. These findings are in agreement with those of other series which showed that renal involvement at the time of diagnosis reduced survival.3 6 [29] [30] [31] It is concluded that SLE, while exceptionally rare in children under 5 years of age, is an important differential diagnosis in the polyarthritis of adolescents, particularly girls. Although prognosis is markedly affected by the early development of nephritis, the improved survival now compares favourably with that seen in adults.
